{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:05:33Z","timestamp":1793502333580,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cgh.2026.01.049","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:20:33Z","timestamp":1772731233000},"page":"2512-2523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn\u2019s Disease: Results From the VIVID-2 Open-Label Extension Trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R.","family":"Hozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul","family":"Gandhi R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle U.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Protic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.01.049_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.01.049_bib2","first-page":"32","article-title":"Increased lifetime risk of intestinal complications and extraintestinal manifestations in Crohn's disease and ulcerative colitis","volume":"18","author":"Lichtenstein","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cgh.2026.01.049_bib3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1007\/s10620-024-08434-5","article-title":"Patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe Crohn's disease in US and Europe: results from the cross-sectional CONFIDE study","volume":"69","author":"Schreiber","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.01.049_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.01.049_bib5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.01.049_bib6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.01.049_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.01.049_bib8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.01.049_bib9","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.01.049_bib10","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"31","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.01.049_bib11","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.01.049_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.01.049_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.01.049_bib14","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2026.01.049_bib15","doi-asserted-by":"crossref","first-page":"i167","DOI":"10.1093\/ecco-jcc\/jjad212.0093","article-title":"DOP53 long-term efficacy and safety of risankizumab in patients with moderate to severe Crohn's disease up to 3 years of treatment: results from the FORTIFY open-label long-term extension","volume":"18","author":"Ferrante","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2026.01.049_bib16","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/ecco-jcc\/jjad212.0010","article-title":"OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn\u2019s disease: results from the U-ENDURE long-term extension","volume":"18","author":"D'Haens","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.01.049_bib17","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/ibd\/izae044","article-title":"Patient perspectives of bowel urgency and bowel urgency-related accidents in ulcerative colitis and Crohn's disease","volume":"30","author":"Jairath","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.01.049_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s41687-019-0154-x","article-title":"A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis","volume":"3","author":"Newton","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.cgh.2026.01.049_bib19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.14309\/ajg.0000000000001685","article-title":"Urgency and its association with quality of life and clinical outcomes in patients with ulcerative colitis","volume":"117","author":"Sninsky","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.01.049_bib20","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.01.049_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.01.049_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","volume":"11","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2026.01.049_bib23","first-page":"13916","article-title":"Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach","volume":"13","author":"Genaro","year":"2021","journal-title":"Am J Transl Res"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526001552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526001552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:02:59Z","timestamp":1787306579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526001552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1542356526001552"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.01.049","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn\u2019s Disease: Results From the VIVID-2 Open-Label Extension Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.01.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}